ArticleJMIR research protocols2025
Effectiveness of Metformin Prolonged-Release Formulation on Achievement of Optimal Glycemic Control in Gestational Diabetes Mellitus: Protocol for a Pilot, Randomized, Double-Blind, Clinical Trial.
Article in JMIR research protocols, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGestational diabetes mellitus (GDM) is one of the most common complications in pregnancy. Optimal glycemic control is key to reducing the risk of adverse pregnancy outcomes. If glycemic control is inadequate, additional medications are needed. A large body of evidence has shown that metformin is an effective medication for GDM. Compared to the immediate-release formulation, the prolonged-release (PR) formulation of metformin offers some advantages with a single daily dose and has less frequent side effects, leading to better compliance. To date, no study has specifically reported the effectiveness of metformin PR in the treatment of GDM or the time required to achieve glycemic control after treatment. The results will help clinicians plan a better choice of treatment and follow-up for women with GDM and inadequate glycemic control.
objectiveThis study aims to evaluate the effectiveness of metformin PR in the treatment of GDM in terms of achieving glycemic control within 6 weeks, time to achieve glycemic control, and associated factors.
methodsA randomized, double-blind, placebo-controlled clinical trial will be conducted among 80 pregnant women diagnosed with GDM who had inadequate glycemic control at a university hospital in Thailand. The women will be randomized into 2 equal groups, receiving either metformin PR or a placebo in addition to nutritional therapy and behavioral modification. Dosage adjustment will be made every 2 weeks. If the glycemic target is not achieved within 6 weeks, insulin therapy will be initiated. All the participants and the investigators are blinded to the treatment provided. The primary outcome is the rate of achievement of glycemic control, and secondary outcomes are time to achieve glycemic control, rate of insulin therapy, and factors associated with the success of metformin PR use.
resultsThe study was funded in May 2025 when recruitment started. The study is projected to be completed in October 2026. Women with GDM who experienced inadequate glycemic control by nutritional therapy were assessed for eligibility. As of October 2025, 24 women with GDM agreed to participate and follow-ups were scheduled. The results are expected to be published in 2027.
conclusionsThe results of this study will provide additional information on the use of metformin in the treatment of GDM, including the use of different formulations, rate of glycemic control, time to achieve glycemic control, and associated factors. This will help physicians better plan care for pregnant women with GDM, especially when glycemic control is inadequate, including choices of metformin formulation and dosage, follow-up schedule, and identification of women at risk of treatment failure.
trial registrationThai Clinical Trial Registry TCTR20250525007; https://www.thaiclinicaltrials.org/show/TCTR20250525007. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/79855.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.